Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-28. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== C-terminal amino acid analysis == The number of methods available for C-terminal amino acid analysis is much smaller than the number of available methods of N-terminal analysis. The most common method is to add carboxypeptidases to a solution of the protein, take samples at regular intervals, and determine the terminal amino acid by analysing a plot of amino acid concentrations against time. This method will be very useful in the case of polypeptides and protein-blocked N termini. C-terminal sequencing would greatly help in verifying the primary structures of proteins predicted from DNA sequences and to detect any posttranslational processing of gene products from known codon sequences.
Improper disposal of the radionuclide cobalt-60, used in cobalt guns for radiotherapy, has led to serious radiation accidents, such as the Ciudad Juárez (Mexico) radiological accident in 1983/84, the Goiânia (Brazil) accident in 1987, the Samut Prakan (Thailand) nuclear accident in 2000, and the Mayapuri (India) accident in 2010. Eleven Therac-25 linear accelerators were built by the Canadian company Atomic Energy of Canada Limited (AECL) between 1982 and 1985 and installed in clinics in the United States and Canada. Software errors and a lack of quality assurance led to a serious malfunction that killed three patients and seriously injured three others between June 1985 and 1987 before appropriate countermeasures were taken. The radiation exposure in the six cases was subsequently estimated to be between 40 and 200 Gray; normal treatment is equivalent to a dose of less than 2 Gray. Around 1990, about one hundred cobalt guns were still in use in Germany. In the meantime, electron linear accelerators were introduced and the last cobalt gun was decommissioned in 2000.
== Associated conditions == Diseases of the pituitary, the gland that produces, among others, the hormone ACTH Hypopituitarism, the hyposecretion of ACTH in the pituitary, leading to secondary adrenal insufficiency (a form of hypocorticism) Addison's disease, the primary adrenal insufficiency (another form of hypocorticism) Cushing's syndrome, hypercorticism, one of the causes is hypersecretion of ACTH Small cell carcinoma, a common cause of ACTH secreted ectopically Congenital adrenal hyperplasia, diseases in the production of cortisol Nelson's syndrome, the rapid enlargement of the ACTH producing pituitary after the removal of both adrenal glands Adrenoleukodystrophy, can be accompanied by adrenal insufficiency West syndrome ("infantile spasms"), a disease where ACTH is used as a therapy Postorgasmic illness syndrome (POIS), through production of tyrosine hydroxylase and dopamine β-hydroxylase, which two enzymes comprise the biochemical mechanism by which norepinephrine and epinephrine are produced. Critical illness-related corticosteroid insufficiency DAVID syndrome, a genetic disorder that is characterized by adrenocorticotropic hormone deficiency combined with common variable immunodeficiency and hypogammaglobulinemia.
== Genetics == The human OPRK1 gene is located on chromosome 8 and comprises four exons separated by three introns, spanning approximately 25 kilobases. The gene utilizes at least three transcription initiation sites, generating mRNAs with 5′-UTRs of 215–299 nucleotides, with the predominant isoform containing 238 nucleotides of 5′-UTR sequence. The exon-intron organization is conserved between human, mouse, and rat OPRK1 genes.
=== Anti-terrorism preparation === Among more than 270,000 US military service members vaccinated with smallpox vaccine between December 2002, and March 2003, eighteen cases of probable myopericarditis were reported (all in first-time vaccinees who received the NYCBOH strain of vaccinia virus), an incidence of 7.8 per 100,000 during the 30 days they were observed. All cases were in young, otherwise healthy adult white men and all survived. In 2002, the United States government started a program to vaccinate 500,000 volunteer health care professionals throughout the country. Recipients were healthcare workers who would be first-line responders in the event of a bioterrorist attack. Many healthcare workers refused or did not pursue vaccination, worried about vaccine side effects, compensation and liability. Most did not see an immediate need for the vaccine. Some healthcare systems refused to participate, worried about becoming a destination for smallpox patients in the event of an epidemic. Fewer than 40,000 actually received the vaccine. On 21 April 2022, Public Services and Procurement Canada published a notice of tender seeking to stockpile 500,000 doses of smallpox vaccine in order to protect against a potential accidental or intentional release of the eradicated virus. On 6 May, the contract was awarded to Bavarian Nordic for their Imvamune vaccine. These were deployed by the Public Health Agency of Canada for targeted vaccination in response to the 2022 mpox outbreak.
Sources: en.wikipedia.org
=== Other methods === Burning sulfur together with saltpeter (potassium nitrate, KNO3), in the presence of steam, has been used historically. As saltpeter decomposes, it oxidizes the sulfur to SO3, which combines with water to produce sulfuric acid. Prior to 1900, most sulfuric acid was manufactured by the lead chamber process. As late as 1940, up to 50% of sulfuric acid manufactured in the United States was produced by chamber process plants. A wide variety of laboratory syntheses are known, and typically begin from sulfur dioxide or an equivalent salt. In the metabisulfite method, hydrochloric acid reacts with metabisulfite to produce sulfur dioxide vapors. The gas is bubbled through nitric acid, which will release brown/red vapors of nitrogen dioxide as the reaction proceeds. The completion of the reaction is indicated by the ceasing of the fumes. This method conveniently does not produce an inseparable mist.
On 27 October 1977, a group of insurgents attacked a SADF patrol in the Cutline, killing 5 South African soldiers and mortally wounding a sixth. As military historian Willem Steenkamp records, "while not a large clash by World War II or Vietnam standards, it was a milestone in what was then...a low intensity conflict". Three months later, insurgents fired on patrols in the Cutline again, killing six more soldiers. The growing number of ambushes and infiltrations were timed to coincide with assassination attempts on prominent South West African tribal officials. Perhaps the most high-profile assassination of a tribal leader during this time was that of Herero chief Clemens Kapuuo, which South Africa blamed on PLAN. Vorster finally acquiesced to Botha's requests for retaliatory strikes against PLAN in Angola, and the SADF launched Operation Reindeer in May 1978. One controversial development of Operation Reindeer helped sour the international community on the South African Border War. On 4 May 1978, a battalion-sized task force of the 44 Parachute Brigade conducted a sweep through the Angolan mining town of Cassinga, searching for what it believed was a PLAN administrative centre.
At least 18 microbial VOCs (MVOCs) have been characterized including 1-octen-3-ol (mushroom alcohol), 3-Methylfuran, 2-pentanol, 2-hexanone, 2-heptanone, 3-octanone, 3-octanol, 2-octen-1-ol, 1-octene, 2-pentanone, 2-nonanone, borneol, geosmin, 1-butanol, 3-methyl-1-butanol, 3-methyl-2-butanol, and thujopsene. The last four are products of Stachybotrys chartarum, which has been linked with sick building syndrome.
== Receptors == The major cell-matrix adhesion receptors are integrins and therefore the adhesome of cell-matrix adhesion is referred to as the integrin adhesome. Cell-cell adhesion is primarily mediated by cadherin receptors and therefore the adhesome of cell-cell adhesion is referred to as the cadherin adhesome or cadhesome. The first attempts to establish the set of proteins that participate directly ('bona fide' adhesome components) or affect indirectly ('associated' adhesome components) cell adhesion were based on mining of the primary research literature, and resulted in approximately 200 protein in either integrin or cadherin adhesomes. Later, unbiased proteomic approaches utilizing mass spectrometry have detected hundreds more proteins associated with integrin adhesions. However, a comparison of multiple proteomic studies of the integrin adhesome of fibroblasts attached to fibronectin found only 60 proteins common to all studies.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.